Business
Biofrontera Inc. Announces Filing of Supplemental New Drug Application (sNDA) for the Treatment of Superficial Basal Cell Carcinoma (sBCC) with Ameluz®-PDT
sNDA for treatment of sBCC with Ameluz®-PDT submitted to U.S. Food and Drug Administration (FDA) on November 28, 2025First Phase 3 PDT study in patients with sBCC in the United States submitted to FDAPrimary and key secondary endpoints met with high statistical significance (p <0.0001)Favorable recurrence outcomes at one-year follow-upBCC is the most common skin cancer in the US with more than 3 million cases diagnosed annually1 WOBURN, Mass., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (
About this update from Biofrontera Inc.
[{"type":"image","alt":"Biofrontera Inc.","displaySize":"","headline":null,"caption":"Biofrontera Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":150,"url":"https://media.zenfs.com/en/globenewswire.com/f8bea715aa1dcdf4aff565eecd02fa4b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/bVH36b1WxYUx1e199mXo7Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIxMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/f8bea715aa1dcdf4aff565eecd02fa4b","width":300,"height":150}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"sNDA for treatment of sBCC with Ameluz®-PDT submitted to U.S. Food and Drug Administration (FDA) on November 28, 2025","length":117,"tagName":"p"}]},{"val":[{"type":"text","content":"First Phase 3 PDT study in patients with sBCC in the United States submitted to FDA","length":83,"tagName":"p"}]},{"val":[{"type":"text","content":"Primary and key secondary endpoints met with high statistical significance (p <0.0001)","length":89,"tagName":"p"}]},{"val":[{"type":"text","content":"Favorable recurrence outcomes at one-year follow-up","length":51,"tagName":"p"}]},{"val":[{"type":"text","content":"BCC is the most common skin cancer in the US with more than 3 million cases diagnosed annually1","length":95,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":435,"olType":false},{"type":"text","content":"WOBURN, Mass., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), today announced the submission of an sNDA to the FDA, seeking approval of Ameluz®-PDT for the treatment of sBCC.","length":340,"tagName":"p"},{"type":"text","content":"The submission includes the full efficacy data sets from the Phase 3 treatment phase and the one-year follow-up, together with an integrated safety assessment combining data from Biofrontera’s U.S. and European Basal Cell Carcinoma clinical studies. The filing seeks to expand the Ameluz® label to include treatment of sBCC treatment with PDT using its BF-RhodoLED® or RhodoLED® XL red light lamps.","length":398,"tagName":"p"},{"type":"text","content":"The double-blind, randomized, placebo-controlled, multi-center Phase 3 study evaluated the safety and efficacy of Ameluz®-PDT in 187 patients with...